Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs EPAM Systems Inc (EPAM) Price & Performance

CVS Health CorpTrade
EPAM Systems IncTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs EPAM Systems Inc — how do they compare? CVS Health Corp trades at $104.32 (market cap $135.48B), while EPAM Systems Inc trades at $84.59 (market cap $4.41B). The key difference: CVS Health Corp is far larger — about 30.7× EPAM Systems Inc's market cap, and CVS Health Corp pays a 2.51% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.

CVSEPAM
Market Cap
$135.48B$4.41B
Sector
HealthTechnology
52-Week High
$106.18$221.40
52-Week Low
$58.75$76.04
Enterprise Value
$202.02B$3.67B
Dividend Yield
2.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.

The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.

EPAM Systems Inc

EPAM trades at $86.38, up 2.97% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows attractive valuation with a P/E of 12.41 and P/S of 0.86, supported by consistent earnings beats in recent quarters. Revenue grew to $5.46B in 2025, though net income margin dipped to 6.96%. Recent news highlights EPAM's AI partnerships and upcoming Q2 earnings, with analyst sentiment strongly bullish.

The outlook for EPAM is positive given its low valuation multiples and strong analyst consensus, with a price target of $128.55 implying significant upside. Risks include competitive pressures in IT services and potential margin compression, but the company's focus on AI transformation and solid cash flow generation provide a foundation for growth. Investors should weigh the high institutional confidence against macroeconomic headwinds affecting the tech sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS

About EPAM Systems Inc

EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.

Read more on EPAM